Characterization of ovarian cancer cell metabolism and response to chemotherapy by 31P magnetic resonance spectroscopy

Oncology Research

Volumn 20, Issue 11, 2013, Pages 529-536

  Abramov, Yoram ^a   Carmi, Shani ^b   Anteby, Shaoul O ^b   Ringel, Israel ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Antimitotic drugs; Glycerophosphocholine; Magnetic resonance spectroscopy (MRS); Ovarian cancer; Paclitaxel; Phospholipid metabolites

Indexed keywords

CARBOPLATIN; CISPLATIN; CREATINE PHOSPHATE; GLYCEROPHOSPHOETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PACLITAXEL; URIDINE DIPHOSPHATE;

ARTICLE; CELL CULTURE; CELL METABOLISM; CONTROLLED STUDY; DRUG RESPONSE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; LC 50; MYCOPLASMA; OVARY CANCER; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOME; OVARIAN NEOPLASMS; PHOSPHORUS; PHOSPHORYLATION;

EID: 84886923818     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13747716581372     Document Type: Article

References (27)

1. Zupke, C.; Foy, B. Nuclear magnetic resonance analysis of cell metabolism. Curr. Opin. Biotechnol. 6:192-197; 1995.
2. 31P MR spectral alterations in human hepatic tumors. NMR Biomed. 11:354-359; 1998.
3. Podo, F. Tumor phospholipid metabolism. NMR Biomed. 12:413-439; 1999.
4. Kaplan, O.; Cohen, J. S. Metabolism of breast cancer cells as revealed by non-invasive magnetic resonance spectroscopy studies. Breast Cancer Res. Treat. 31:285-299; 1994.
5. Ruiz-Cabello, J.; Cohen, J. S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 5:226-233; 1992.
6. Barzilai, A.; Horowitz, A.; Geier, A.; Degani, H. Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A NMR study. Cancer 67:2919-2925; 1991.
7. Cohen, J. S.; Jaroszewski, J. W.; Kaplan, O.; Ruiz-Cabello, J.; Collier, S. A history of biological applications of NMR spectroscopy. J. Prog. Nucl. Magn. Reson. Spectrosc. 28:53-85; 1995.
8. 31P magnetic resonance spectroscopy. Cancer Res. 46:4087-4090; 1986.
9. Kaplan, O.; Jaroszewski, J. W.; Faustino, P. J.; Zugmaier, G.; Ennis, B. W.; Lippman, M. Toxicity and effects of epidermal growth factor on glucose metabolism of MDA-468 human breast cancer cells. J. Biol. Chem. 265:13641-13649; 1990.
10. 13C MRS studies. Proc. Natl. Acad. Sci. USA 86:5585-5589; 1989.
11. Galons, J. P.; Fantini, J.; Vion-Dury, J.; Cozzone, P. J.; Canioni, P. Metabolic changes in undifferentiated and differentiated human colon adenocarcinoma cells studied by multinuclear magnetic resonance spectroscopy. Biochimie 71:949-961; 1989.
12. 31P NMR studies. Breast Cancer Res. Treat. 33:209-217; 1995.
13. Neeman, M.; Degani, H. Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells by nuclear magnetic resonance spectroscopy. Cancer Res. 49:589-594; 1989.
14. 31P-magnetic resonance spectroscopy study. Cancer Res. 61:7536-7543; 2001.
15. 31P-MRS studies. Biochim. Biophys. Acta 1052:36-41; 1990.
16. Kaplan, O.; Navon, G.; Lyon, R. C.; Faustino, P. J.; Straka, E. J.; Cohen, J. S. Effects of 2-deoxyglucose on drugsensitive and drug-resistant breast cancer cells: Toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res. 50:544-551; 1990.
17. Maymon, R.; Bar, S.; Maymon, B.; Holzinger, M.; Tartskovsky, B.; Leibovici, J. Augmentative effect of intracellular chemotherapy penetration combined with hyperthermia in human ovarian cancer cell lines. Gynecol. Oncol. 55:265-270; 1994.
18. Public Health England. European Collection of Cell Cultures: General cell collection. Retrieved from http://www.hpacultures. org.uk/products/celllines/ generalcell/search.jsp
19. Mackinnon, W. B.; Russell, P.; May, G. L.; Mountford, C. E. Characterization of human ovarian epithelial tumors (ex vivo) by proton magnetic resonance spectroscopy. Int. J. Gynecol. Cancer 5:211-221; 1995.
20. 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn. Reson. Med. 38:569-576; 1997.
21. Schiffenbauer, Y. S.; Abramovitch, R.; Meir, G.; Nevo, N.; Holzinger, M.; Itin, A.; et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc. Nat. Acad. Sci. USA 94:13203-13208; 1997.
22. 1H NMR of tissue biopsies. Biochem. Cell Biol. 76:472-476; 1998.
23. Fong, M. Y.; McDunn, J.; Kakar, S. S. Identification of the metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PloS One 6:e19963; 2011.
24. Kunz-Schughart, L. A.; Freyer, J. P. Phosphorous metabolites and steady-state energetics of transformed fibroblasts during three-dimensional growth. Am. J. Physiol. 283:C1287-C1297; 2002.
25. Hakumäki, J. M.; Brindle, K. M. Techniques: Visualizing apoptosis using nuclear magnetic resonance. Trends Pharmacol. Sci. 24:146-149; 2003.
26. Iorio, E.; Mezzanzanica, D.; Alberti, P.; Spadaro, F.; Ramoni, C.; D'Ascenzo, S., et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 65:9369-9376; 2005.
27. Montopoli, M.; Bellanda, M.; Lonardoni, F.; Ragazzi, E.; Dorigo, P.; Froldi, G.; Mami, S.; Caparrotta, L. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin. Curr. Cancer Drug Targets 11:226-235; 2011.